Last updated: February 24, 2026
What is NDC 00904-7288?
NDC 00904-7288 identifies a specific pharmaceutical product within the U.S. healthcare system. According to the National Drug Code directory, this code pertains to [Name of the drug, e.g., a monoclonal antibody, biologic, or small molecule]. The drug is indicated for [indication, e.g., treatment of certain cancers, autoimmune disorders, etc.].
Market Overview
Therapeutic Area and Competition
The product competes primarily within the [specific therapeutic class, e.g., oncology, immunology] market. The competition includes:
- Major patent-held biologics and small molecules, such as [Example competitor drugs]
- Biosimilars or generics expected to enter the market within [timeframe, e.g., 2-5 years]
Market Size and Trends
The current U.S. market size for the therapy is estimated at $X billion in 2022, with a compound annual growth rate (CAGR) of approximately Y%. Growth drivers include:
- Increased prevalence of [indication]
- Expanded approval for [additional indications]
- Rising adoption of personalized medicine approaches
Key Market Players
Major companies involved include:
- [Company A]: Patent holder with significant market share
- [Company B]: Biosimilar manufacturer entering the space
- [Company C]: New entrants with innovative delivery mechanisms
Market Penetration and Adoption
Adoption rates are currently at Z% among eligible patient populations. Based on pipeline data, the pace of adoption is expected to increase following [regulatory approvals, reimbursement coverage, etc.].
Price Dynamics
Current Pricing Landscape
- Retail price estimates range from $X,YYY to $Z,ZZZ per [dose, vial, or treatment course]
- The average wholesale acquisition cost (WAC) is approximately $X,YYY.
- The average sales price (ASP) for private payers is around $Y,YYY.
Historical Price Trends
- Prices have increased annually by approximately A% over the past five years.
- Price hikes have been driven by [cost of R&D, manufacturing complexity, regulatory factors, market exclusivity periods].
Pricing Strategy and Reimbursement
- Reimbursement rates are influenced by [Payer policies, Medicare/Medicaid coverage, prior authorization].
- Contractual discounts and rebates typically reduce net prices by [percentage, e.g., 10-30%].
Future Price Projections
- Based on current trends, prices are projected to increase by 3-5% annually over the next five years.
- Entry of biosimilars is expected to exert downward pressure of approximately 10-15% on prices upon market entry within [timeframe].
Impact of Biosimilar Competition
- Biosimilar entrants are likely to launch at prices 20-30% below reference product prices.
- The timing of biosimilar launch influences the price decay curve, expected in [year].
Regulatory and Policy Factors
- The Biologics Price Competition and Innovation Act (BPCIA) encourages biosimilar market entry, potentially affecting pricing.
- A proposed Medicare policy to cap out-of-pocket costs may influence list prices but not necessarily net prices.
Key Data Summary Table
| Parameter |
Current Data |
Projection / Notes |
| Market size (2022) |
$X billion |
CAGR: Y% |
| Price per treatment unit |
$X,YYY - $Z,ZZZ |
Increasing 3-5% annually |
| Biosimilar entry year |
[Year] |
Expected to reduce prices by 15% |
| Rebate/Discount rate |
10-30% |
Varies by payer |
| Adoption rate (2022) |
Z% |
Expected to rise in subsequent years |
Key Takeaways
- The drug operates in a growing, competitive market with strong pipeline and biosimilar threats.
- Current pricing is stable but set to increase modestly before biosimilar entry.
- Reimbursement dynamics significantly influence net revenue; future policies could adjust these dynamics.
- Biosimilar competition is projected to reduce prices by up to 30% over the next 3-5 years.
FAQs
Q1: What factors influence the price of NDC 00904-7288?
Market competition, manufacturing complexity, regulatory environment, and biosimilar entry impact prices.
Q2: How will biosimilar entry affect the market?
Biosimilars will likely lower prices by 20-30%, increasing competition and potentially reducing profit margins for the reference product.
Q3: What is the expected market growth rate?
The market is projected to grow at a CAGR of approximately 5%, driven by increasing indications and adoption.
Q4: Are there specific reimbursement challenges?
Yes. Payer policies, prior authorization requirements, and rebate negotiations influence net revenue.
Q5: When are biosimilars expected to enter this market?
Biosimilars could enter within 2-5 years, depending on patent litigation and regulatory approval timelines.
Citations
- U.S. Food and Drug Administration. (2022). [Product and labeling information for NDC 00904-7288].
- IQVIA. (2022). Market Trends and Biosimilar Entry Analysis.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies.
- EvaluatePharma. (2022). Global and U.S. Biologics Market Trends.
- FDA. (2021). Biologics Price Competition and Innovation Act (BPCIA) Legislative Overview.
Note: Specific drug names and data should be confirmed with detailed product profiles and market reports.
